The conversation discusses a hair loss treatment regimen that includes scalp massage, derma rolling, saw palmetto, rosemary, peppermint oil, pumpkin seed oil, and various supplements like vitamins C and D, multivitamins, biotin, collagen, and fish oil. The user is asking if the treatment has led to hair regrowth.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.
The user is experiencing noticeable hair thickening after 4 months of using a topical spray combining minoxidil and finasteride, with no side effects reported. They are considering adding derma rolling to their routine and may switch to oral tablets in the future.
A user shared their 20-week progress using topical minoxidil (5%) and finasteride (0.1%) with a 1mm dermastamp, showing significant hair regrowth from NW5 to between NW3V and NW4. They experienced no side effects and plan to update at 12 months.
After a hair transplant, the user noticed unexpected new hair growth without using medications or vitamins. Many advised starting treatments like minoxidil and finasteride to maintain the results and prevent future hair loss.
Hair loss treatments, ranging from topical minoxidil and finasteride to taking hormones such as estradiol or nandrolone, as well as a controversial suggestion of an orchiectomy. A hair system is also mentioned as an alternative solution.
RU58841's side effects may be exaggerated due to anxiety, with some users experiencing no issues and others reporting symptoms like chest pain. RU58841, minoxidil, and finasteride are used for hair loss treatment, with varying individual reactions.
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.
The conversation is about someone using topical dutasteride and oral minoxidil for hair loss, and they are seeking opinions on potential hair regrowth shown in a photo. Respondents agree that there is some progress.
Hair regrowth treatment involving 3aHSD enzyme shows 6% improvement in 18 weeks. Sulforaphane, L-Menthol, and Dexpanthenol are potential ingredients for new hair loss solution.
Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.
The user has low testosterone and DHT levels and is considering taking finasteride for Norwood 2 hair loss with diffuse thinning. They are seeking advice on whether low DHT indicates high sensitivity to DHT in the scalp and opinions on their lab values.
The user is seeking advice on a hair loss treatment called Ell Cranell, which contains Alfatradiol. Another user shared information from a study stating that Alfatradiol only slows down or stabilizes hair loss, but does not increase hair density or thickness.
The user reports positive progress in hair regrowth using 1mg oral finasteride, 3mg oral minoxidil, biotin, vitamin D, red light therapy, and microneedling. They note thickening at the hairline and some regrowth at the temples.
Finasteride's effectiveness and side effects may vary based on male phenotypes, with some users noting differences in response related to body and facial hair characteristics. Some users report success with lower doses, while others experience side effects, suggesting individual variability in response to the treatment.
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.
The conversation is about creating a homemade solution for hair loss treatment, specifically asking for advice on what base to use for topical melatonin. No specific treatments were discussed.
A user experienced unexpected hormone test results after 7 months on 1mg daily finasteride, noting a decrease in estradiol despite expectations of an increase. Other users suggested that hormone responses can vary and that finasteride might still be effective if DHT levels are within range, while also mentioning factors like circadian rhythm and stress that could impact results.
PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.
The user shares their experience with a hair system, noting no one noticed the change except their girlfriend. They discuss the learning curve, maintenance tips, and their satisfaction with the results, feeling more confident and optimistic.
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.